Advertisement
| artemisinin-based combination therapies: Saving Lives, Buying Time Institute of Medicine, Board on Global Health, Committee on the Economics of Antimalarial Drugs, 2004-09-09 For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world. Malaria deaths in sub-Saharan Africaâ€currently just over one million per yearâ€are rising because of increased resistance to the old, inexpensive drugs. Although effective new drugs called artemisinins are available, they are unaffordable for the majority of the affected population, even at a cost of one dollar per course. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance examines the history of malaria treatments, provides an overview of the current drug crisis, and offers recommendations on maximizing access to and effectiveness of antimalarial drugs. The book finds that most people in endemic countries will not have access to currently effective combination treatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify. |
| artemisinin-based combination therapies: Economic Analysis of Malaria Control in Sub-Saharan Africa Catherine Cavallaro Goodman, Paul W. Coleman, Anne Mills, 2000 |
| artemisinin-based combination therapies: Guidelines for the Treatment of Malaria World Health Organization, 2010 The purpose of this document is to provide comprehensible, global, evidence-based guidelines to help formulate policies and protocols for the treatment of malaria. Information is presented on the treatment of uncomplicated malaria, including disease in special groups (young children, pregnant women, people who are HIV positive, travellers from non-malaria endemic regions) and in complex emergency situations and severe malaria.--Publisher's description. |
| artemisinin-based combination therapies: Malaria Control During Mass Population Movements and Natural Disasters Program on Forced Migration and Health at the Mailman School of Public Health of Columbia University, National Research Council, Committee on Population, Roundtable on the Demography of Forced Migration, Holly A. Williams, Peter B. Bloland, 2003-01-16 Admittedly, the world and the nature of forced migration have changed a great deal over the last two decades. The relevance of data accumulated during that time period can now be called into question. The roundtable and the Program on Forced Migration at the Mailman School of Public Health of Columbia University have commissioned a series of epidemiological reviews on priority public health problems for forced migrants that will update the state of knowledge. Malaria Control During Mass Population Movements and Natural Disasters- the first in the series, provides a basic overview of the state of knowledge of epidemiology of malaria and public health interventions and practices for controlling the disease in situations involving forced migration and conflict. |
| artemisinin-based combination therapies: Guidelines for the Treatment of Malaria. Third Edition World Health Organization, 2015-08-13 Malaria remains an important cause of illness and death in children and adults in countries in which it is endemic. Malaria control requires an integrated approach including prevention (primarily vector control) and prompt treatment with effective antimalarial agents. Malaria case management consisting of prompt diagnosis and effective treatment remains a vital component of malaria control and elimination strategies. Since the publication of the first edition of the Guidelines for the treatment of malaria in 2006 and the second edition in 2010 all countries in which P. falciparum malaria is endemic have progressively updated their treatment policy from use of ineffective monotherapy to the currently recommended artemisinin-based combination therapies (ACT). This has contributed substantially to current reductions in global morbidity and mortality from malaria. Unfortunately resistance to artemisinins has arisen recently in P. falciparum in South-East Asia which threatens these gains. This third edition of the WHO Guidelines for the treatment of malaria contains updated recommendations based on a firmer evidence base for most antimalarial drugs and in addition include recommendation on the use of drugs to prevent malaria in groups at high risk. The Guidelines provide a framework for designing specific detailed national treatment protocols taking into account local patterns of resistance to antimalarial drugs and health service capacity. It provides recommendations on treatment of uncomplicated and severe malaria in all age groups all endemic areas in special populations and several complex situations. In addition on the use of antimalarial drugs as preventive therapy in healthy people living in malaria-endemic areas who are high risk in order to reduce morbidity and mortality from malaria. The Guidelines are designed primarily for policy-makers in ministries of health who formulate country-specific treatment guidelines. Other groups that may find them useful include health professionals and public health and policy specialists that are partners in health or malaria control and the pharmaceutical industry. The treatment recommendations in the main document are brief; for those who wish to study the evidence base in more detail a series of annexes is provided with references to the appropriate sections of the main document. |
| artemisinin-based combination therapies: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| artemisinin-based combination therapies: Global Report on Antimalarial Drug Efficacy and Drug Resistance , 2010 This report provides a comprehensive, global overview of antimalarial drug efficacy and the resistance of malaria parasites to the antimalarial medicines used between 2000 and June 2010. Policy-makers in national ministries of health will benefit from this document, as it provides both a global and a regional picture of the efficacy of the antimalarial medicines currently used in national treatment programmes. In addition, the report will be a reference for scientists, enhancing their understanding of the complexity of antimalarial drug resistance. |
| artemisinin-based combination therapies: CDC Yellow Book 2020 Centers for Disease Control and Prevention (CDC), 2019 The definitive reference for travel medicine, updated for 2020 A beloved travel must-have for the intrepid wanderer. -Publishers Weekly A truly excellent and comprehensive resource. -Journal of Hospital Infection The CDC Yellow Book offers everything travelers and healthcare providers need to know for safe and healthy travel abroad. This 2020 edition includes: � Country-specific risk guidelines for yellow fever and malaria, including expert recommendations and 26 detailed, country-level maps � Detailed maps showing distribution of travel-related illnesses, including dengue, Japanese encephalitis, meningococcal meningitis, and schistosomiasis � Guidelines for self-treating common travel conditions, including altitude illness, jet lag, motion sickness, and travelers' diarrhea � Expert guidance on food and drink precautions to avoid illness, plus water-disinfection techniques for travel to remote destinations � Specialized guidelines for non-leisure travelers, study abroad, work-related travel, and travel to mass gatherings � Advice on medical tourism, complementary and integrative health approaches, and counterfeit drugs � Updated guidance for pre-travel consultations � Advice for obtaining healthcare abroad, including guidance on different types of travel insurance � Health insights around 15 popular tourist destinations and itineraries � Recommendations for traveling with infants and children � Advising travelers with specific needs, including those with chronic medical conditions or weakened immune systems, health care workers, humanitarian aid workers, long-term travelers and expatriates, and last-minute travelers � Considerations for newly arrived adoptees, immigrants, and refugees Long the most trusted book of its kind, the CDC Yellow Book is an essential resource in an ever-changing field -- and an ever-changing world. |
| artemisinin-based combination therapies: Management of Severe Malaria World Health Organization, 2000-04 Malaria continues to be a major health problem in many parts of the world, with over 2,400 million people in 100 countries at risk of infection. This handbook is an updated edition of 'Management of severe and complicated malaria', providing practical guidance on the diagnosis and management of severe falciparum malaria, a form of the disease that can have life-threatening complications if treatment is delayed. |
| artemisinin-based combination therapies: World Malaria Report 2008 World Health Organization, 2008 Curious kids will delight in the joy of scientific discovery through the fifty fun activities in The Budding Scientist! This book is filled with great ways for you and your child to learn about how our world works. Create memories together as you make invisible ink, explore ice crystals, and investigate magnets. Perfect for children ages three to six, this fun-filled introduction to science features easy-to-follow instructions and easy-to-find materials that will help you satisfy your child’s natural curiosity. |
| artemisinin-based combination therapies: Antimalarial Chemotherapy Philip J. Rosenthal, 2001-04-01 Philip Rosenthal, MD, and a panel of leading malaria experts drawn from academia, the military, and international health organizations survey the latest scientific understanding of antimalarial chemotherapy, emphasizing the molecular mechanisms of resistance and the description of important new targets. Their survey covers the current status of malarial and antimalarial chemotherapy, the relevant biology and biochemistry of malaria parasites, the antimalarial drugs currently available, new chemical approaches to chemotherapy, and possible new targets for chemotherapy. Comprehensive and cutting-edge, Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery clearly delineates all the basic and clinical research now addressing one of the world's major unresolved disease problems, work that is now powerfully driving the rapid pace of antimalarial drug discovery today. |
| artemisinin-based combination therapies: World Malaria Report 2015 World Health Organization, 2016-01-30 The World Malaria Report 2015assesses global malaria disease trends and changes in the coverage and financing of malaria control programs between 2000 and 2015. It also summarizes progress towards international targets, and provides regional and country profiles that summarize trends in each WHO region and each country with malaria. The report is produced with the help of WHO regional and country offices, ministries of health in endemic countries, and a broad range of other partners. The data presented are assembled from the 96 countries and territories with ongoing malaria transmission, and a further five countries that have recently eliminated malaria. Most data are those reported for 2014 and 2015, although in some cases projections have been made into 2015, to assess progress towards targets for 2015. |
| artemisinin-based combination therapies: Global Technical Strategy for Malaria 2016-2030 World Health Organization, 2015-11-04 The World Health Organization's Global Technical Strategy for Malaria 2016- 2030 has been developed with the aim to help countries to reduce the human suffering caused by the world's deadliest mosquito-borne disease. Adopted by the World Health Assembly in May 2015 it provides comprehensive technical guidance to countries and development partners for the next 15 years emphasizing the importance of scaling up malaria responses and moving towards elimination. It also highlights the urgent need to increase investments across all interventions - including preventive measures diagnostic testing treatment and disease surveillance- as well as in harnessing innovation and expanding research. By adopting this strategy WHO Member States have endorsed the bold vision of a world free of malaria and set the ambitious new target of reducing the global malaria burden by 90% by 2030. They also agreed to strengthen health systems address emerging multi-drug and insecticide resistance and intensify national cross-border and regional efforts to scale up malaria responses to protect everyone at risk. |
| artemisinin-based combination therapies: The Garki Project L. Molineaux, G. Gramiccia, 1980 |
| artemisinin-based combination therapies: World Malaria Report 2019 World Health Organization, 2019-08-28 The World Malaria Report 2019 provides a comprehensive update on global and regional malaria data and trends. The report tracks investments in malaria programs and research as well as progress across all intervention areas: prevention, diagnosis, treatment, elimination, and surveillance. It also includes dedicated chapters on the consequences of malaria on maternal infant and child health the High Burden to High Impact approach as well as biological threats to the fight against malaria. The 2019 report is based on information received from more than 80 countries and areas with ongoing malaria transmission. This information is supplemented by data from national household surveys and databases held by other organizations. |
| artemisinin-based combination therapies: World Malaria Report 2018 World Health Organization, 2019-02-12 This year s report shows that after an unprecedented period of success in global malaria control progress has stalled. Data from 2015?2017 highlight that no significant progress in reducing global malaria cases was made in this period. There were an estimated 219 million cases and 435 000 related deaths in 2017. The World malaria report 2018 draws on data from 90 countries and areas with ongoing malaria transmission. The information is supplemented by data from national household surveys and databases held by other organizations. |
| artemisinin-based combination therapies: Population and Health in Developing Countries: Population, health and survival at INDEPTH sites International Development Research Centre (Canada), INDEPTH Network, 2002 Population and Health in Developing Countries: Volume 1. Poulation, health, and survival at INDEPTH sites |
| artemisinin-based combination therapies: Towards Malaria Elimination Sylvie Manguin, Vas Dev, 2018-07-18 Towards Malaria Elimination - A Leap Forward was started to mark the occasion for renewed commitment to end malaria transmission for good (the WHO's call for Malaria Free World by 2030). This book is dedicated for the benefit of researchers, scientists, program and policy managers, students and anyone interested in malaria and other mosquito-borne diseases with the goal of sharing recent information on success stories, innovative control approaches and challenges in different regions of the world. Some main issues that emerged included multidrug-resistant malaria and pandemic risk, vaccines, cross-border malaria, asymptomatic parasite reservoir, the threat of Plasmodium vivax and Plasmodium knowlesi, insecticide resistance in Anopheles vectors and outdoor malaria transmission. This book is one little step forward to bring together in 17 chapters the experiences of malaria-expert researchers from five continents to present updated information on disease epidemiology and control at the national/regional level, highlighting the constraints, challenges, accomplishments and prospects of malaria elimination. |
| artemisinin-based combination therapies: Medicinal Natural Products: A Disease-Focused Approach , 2020-09-21 Medicinal Natural Products: A Disease-Focused Approach, Volume 55 in the Annual Reports in Medicinal Chemistry series, highlights the applications of natural products as medicines or prospective medicinal leads for the treatment of various human ailments. Each chapter covers a particular disease area or medical condition, with chapters in this new release covering Medicinal Natural Products – An Introduction, Anticancer Natural Products, Antimicrobial Natural Products, Antimalarial and Antiparasitic Natural Products, Anti-inflammatory Natural Products, Neuroprotective Natural Products, Hepatoprotective Natural Products, Nephroprotective Natural Products, Cancer Chemopreventive Natural Products, Antipsoriatic Natural Products, Medicinal Natural Products in Osteoporosis, Antidiabetic Natural Products, Anti-obesity Natural Products, and much more. - Presents a disease-focused perspective - Includes the latest on the medicinal chemistry of natural products - Covers natural products in drug delivery |
| artemisinin-based combination therapies: Artemisinin-Based and Other Antimalarials Guoqiao Li, Ying Li, Zelin Li, Meiyi Zeng, 2017-11-28 Artemisinin-Based and Other Antimalarials: Detailed Account of Studies by Chinese Scientists Who Discovered and Developed Them provides a historical and scientific background of the discovery and development of artemisinin, artemisinin derivatives, combination drugs and related chemicals. It is a historical document, a scientific treatise, and a fascinating description of innovative research on new drug development that is carried out under extremely difficult conditions. The book also includes detailed experiments, physical-chemical procedures, practical methodologies and clinical trials. It is a valuable reference for students and researchers in the fields of scientific history, medicine, pharmaceutical science, chemistry, pharmacology and toxicology. - Presents details of all stages of drug development, including in vitro experiment, animal exploratory studies, animal tests for toxicity, safety and efficacy followed by stages I, II, III and IV, safety and efficacy in human volunteers and patients with malaria - Provides many physical-chemical laboratory procedures, such as NMR, MS, HPLC and X-ray diffraction used in drug development - Includes practical methodology of clinical trials from many research centers and countries to demonstrate the importance of this discovery |
| artemisinin-based combination therapies: Genetics and Evolution of Infectious Diseases Michel Tibayrenc, 2024-07-19 Genetics and Evolution of Infectious Diseases, Third Edition discusses the evolving field of infectious diseases and their continued impact on the health of populations, especially in resource-limited areas of the world where they must confront the dual burden of death and disability due to infectious and chronic illnesses. Although substantial gains have been made in public health interventions for the treatment, prevention, and control of infectious diseases, in recent decades the world has witnessed the emergence of the human immunodeficiency virus (HIV) and the COVID-19 pandemic, increasing antimicrobial resistance, and the emergence of many new bacterial, fungal, parasitic, and viral pathogens. Fully updated and revised, this new edition presents the consequences of such diseases, the evolution of infectious diseases, the genetics of host-pathogen relationship, and the control and prevention strategies that are, or can be, developed. This book offers valuable information to biomedical researchers, clinicians, public health practitioners, decisions-makers, and students and postgraduates studying infectious diseases, microbiology, medicine, and public health that is relevant to the control and prevention of neglected and emerging worldwide diseases. - Takes an integrated approach to infectious diseases - Provides the latest developments in the field of infectious diseases - Focuses on the contribution of evolutionary and genomic studies for the study and control of transmissible diseases - Includes updated and revised contributions from leading authorities, along with six new chapters |
| artemisinin-based combination therapies: Advances in Malaria Research Deepak Gaur, Chetan E. Chitnis, Virander S. Chauhan, 2016-12-27 Thoroughly reviews our current understanding of malarial biology Explores the subject with insights from post-genomic technologies Looks broadly at the disease, vectors of infection, and treatment and prevention strategies A timely publication with chapters written by global researchers leaders |
| artemisinin-based combination therapies: Disease Control Priorities, Third Edition (Volume 6) King K. Holmes, Stefano Bertozzi, Barry R. Bloom, Prabhat Jha, 2017-11-06 Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings. |
| artemisinin-based combination therapies: Drug Repurposing in Cancer Therapy Kenneth K.W. To, William C.S. Cho, 2020-07-29 Drug Repurposing in Cancer Therapy: Approaches and Applications provides comprehensive and updated information from experts in basic science research and clinical practice on how existing drugs can be repurposed for cancer treatment. The book summarizes successful stories that may assist researchers in the field to better design their studies for new repurposing projects. Sections discuss specific topics such as in silico prediction and high throughput screening of repurposed drugs, drug repurposing for overcoming chemoresistance and eradicating cancer stem cells, and clinical investigation on combination of repurposed drug and anticancer therapy. Cancer researchers, oncologists, pharmacologists and several members of biomedical field who are interested in learning more about the use of existing drugs for different purposes in cancer therapy will find this to be a valuable resource. - Presents a systematic and up-to-date collection of the research underpinning the various drug repurposing approaches for a quick, but in-depth understanding on current trends in drug repurposing research - Brings better understanding of the drug repurposing process in a holistic way, combining both basic and clinical sciences - Encompasses a collection of successful stories of drug repurposing for cancer therapy in different cancer types |
| artemisinin-based combination therapies: CDC Yellow Book 2018: Health Information for International Travel Centers for Disease Control and Prevention CDC, 2017-04-17 THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad. |
| artemisinin-based combination therapies: Treatment and Prevention of Malaria Henry M. Staines, Sanjeev Krishna, 2012-01-06 Malaria has defeated previous efforts at eradication and remains a massive global public health problem despite being readily preventable and treatable. It is a devastating disease that also extracts huge economic costs from the poorest countries in endemic regions. Starting with an overview of the disease and its current political, financial and technical context, this Milestones in Drug Therapy volume describes the history, chemistry, mechanisms of action and resistance, preclinical and clinical use, pharmacokinetics and safety and tolerability of the current range of antimalarial drugs. There is particular emphasis on artemisinins and related peroxides, as these drugs have now become the frontline treatment for malaria. Next generation antimalarials, molecular markers for detecting resistance, the importance of diagnostics and disease prevention are also covered in detail. |
| artemisinin-based combination therapies: Tu Youyou And The Discovery Of Artemisinin: 2015 Nobel Laureate In Physiology Or Medicine Yi Rao, Daqing Zhang, Runhong Li, 2016-09-28 Nobel laureate Tu Youyou won the 2015 prize for Medicine/Physiology for the discovery of artemisinin, a drug therapy for malaria that has saved millions across the globe.This book traces the path of discovery beginning with Chairman Mao's 1964 instruction to Chinese researchers to find a cure for malaria, a disease that plagued the military and civilians alike in endemic regions. It chronicles the years of painstaking research to find effective anti-malarial drugs, and how an entry in a collection of traditional Chinese medicine prescriptions gave Tu Youyou the clue which led her to successfully extract artemisinin from the plant, Artemisia annua.Gathering together information from a variety of sources including first-hand accounts, this book describes the contributions of the many organisations, scientists, doctors and countless others who played a part in the process of discovery and clinical testing. It also provides insights into the challenges of carrying out such an extensive research project with limited resources during the upheavals of the Cultural Revolution. An inspirational read for young scientists.Includes the translation of Professor Tu Youyou's 2015 Nobel Lecture. |
| artemisinin-based combination therapies: Ethics and Drug Resistance: Collective Responsibility for Global Public Health Euzebiusz Jamrozik, Michael Selgelid, 2021-08-21 This Open Access volume provides in-depth analysis of the wide range of ethical issues associated with drug-resistant infectious diseases. Antimicrobial resistance (AMR) is widely recognized to be one of the greatest threats to global public health in coming decades; and it has thus become a major topic of discussion among leading bioethicists and scholars from related disciplines including economics, epidemiology, law, and political theory. Topics covered in this volume include responsible use of antimicrobials; control of multi-resistant hospital-acquired infections; privacy and data collection; antibiotic use in childhood and at the end of life; agricultural and veterinary sources of resistance; resistant HIV, tuberculosis, and malaria; mandatory treatment; and trade-offs between current and future generations. As the first book focused on ethical issues associated with drug resistance, it makes a timely contribution to debates regarding practice and policy that are of crucial importance to global public health in the 21st century. |
| artemisinin-based combination therapies: A Detailed Chronological Record of Project 523 and the Discovery and Development of Qinghaosu (Artemisinin) Zhang Jianfang, 2013 This is an account of a project in China carried out in secrecy from the Chinese people and the Western World during the tumultuous years of the Cultural Revolution. Project 523, as it was called, resulted in one of the most significant advances in the treatment of malaria since the discovery and first use of quinine over 300 years ago. The origin of the project was a request from the North Vietnamese Government to Mao Zedong in China, for assistance in managing chloroquine drug-resistant malaria affecting their military forces during the Vietnam-American war. Initially the project was directed by the Chinese military medical research authorities, but it became so large that civilian scientists were called upon to help. Ultimately, to accomplish this task, over 60 institutions and more than 500 scientists and other personnel scattered throughout mainland China became involved. This achievement is all the more remarkable because it was accomplished during the Cultural Revolution using obsolete equipment, and at a time when all regular research was halted, scientists were harassed and denigrated, and academic and intellectual activity was discouraged or even forbidden. The drug discovered - artemisinin from the plant Qinghao (Artemisia annua L) - is now the most widely used treatment for malaria in the world. |
| artemisinin-based combination therapies: Antimalarial Natural Products A. Douglas Kinghorn, Heinz Falk, Simon Gibbons, Yoshinori Asakawa, Ji-Kai Liu, Verena M. Dirsch, 2022-01-02 This volume begins with a short history of malaria and follows with a summary of its biology. It then traces the fascinating history of the discovery of quinine for malaria treatment, and then describes quinine’s biosynthesis, its mechanism of action, and its clinical use, concluding with a discussion of synthetic antimalarial agents based on quinine’s structure. It also covers the discovery of artemisinin and its development as the source of the most effective current antimalarial drug, including summaries of its synthesis and biosynthesis, its mechanism of action, and its clinical use and resistance. A short discussion of other clinically used antimalarial natural products leads to a detailed treatment of additional natural products with significant antiplasmodial activity, classified by compound type. Although the search for new antimalarial natural products from Nature’s combinatorial library is challenging, it is very likely to yield new antimalarial drugs. This book thus ends by identifying ten natural products with development potential as clinical antimalarial agents. |
| artemisinin-based combination therapies: Approaches to Design and Synthesis of Antiparasitic Drugs N. Anand, S. Sharma†, 1997-07-10 This book presents a comprehensive and up to date account of the chemotherapy of parasitic diseases, both human and veterinary. The book starts with an overview of parasitic diseases. The body of the book is divided into two parts: antihelminthic drugs, and antiprotozoal drugs. Both parts start with chapters highlighting the 'biochemical targets' available for chemotherapeutic interference. Individual chapters deal with one chemical class of compounds and describe their origin, structure-activity relationship, mode of action, and methods of synthesis and their status both in clinical and veterinary practice. The book will be useful to a wide spectrum of readers: students embarking on a research career in parasitic chemotherapy, clinicians (and veterinarians) and clinical pharmacologists desiring detailed information about the drugs currently in use, and pharmaceutical technologists wanting to update their knowledge of the methods of manufacture. |
| artemisinin-based combination therapies: Rolling Back Malaria World Bank, 2005 There are more than 1.1 million deaths per year from malaria, mostly among children less than five years old. The disease is preventable and curable with available technologies, but , in the absence of strong and sustained malaria control efforts, coverage with effective interventions is low, particularly among the poor. Malaria impairs economic growth and human development in many of the World Bank's client countries, particularly in Sub-Saharan Africa. The Bank has the capacity to do a lot more than it has in malaria control, including financing, policy advice, and implementation support. It will support countries to develop and implement programs to (i) cost-effectively reduce morbidity, productivity losses in multiple sectors, and mortality due to malaria, particularly among the poor and among children and pregnant women; and (ii) address the challenges of regional and global public goods. |
| artemisinin-based combination therapies: Vector-Borne Diseases David Claborn, Sujit Bhattacharya, Syamal Roy, 2020-06-03 Vector-Borne Diseases - Recent Developments in Epidemiology and Control utilizes the unique capabilities of open-access publishing to share exciting developments in the biology, diagnosis, and treatment of diseases spread by arthropods. From malaria to dengue to leishmaniasis, the diseases addressed in this book continue to present threats to the life and well-being of millions around the world. The international cast of writers published here provide specific insight into a full spectrum of diseases spread by insects and their close relatives. |
| artemisinin-based combination therapies: The Travel and Tropical Medicine Manual E-Book Christopher A. Sanford, Elaine C. Jong, Paul S. Pottinger, 2016-08-07 Prevent, evaluate, and manage diseases that can be acquired in tropical environments and foreign countries with The Travel and Tropical Medicine Manual. This pragmatic resource equips medical providers with the knowledge they need to offer effective aid, covering key topics in pre- and post-travel medicine, caring for immigrants and refugees, and working in low-resource settings. It's also the perfect source for travelers seeking quick, easy access to the latest travel medicine information. - Dynamic images illustrate key concepts for an enhanced visual understanding. - Evidence-based treatment recommendations enable you to manage diseases confidently. - Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, images, and references from the book on a variety of devices. - Evidence-based appendix, available at Expert Consult, helps to validate treatments. - Highlights new evidence and content surrounding mental health and traveling. - Covers emerging hot topics such as Ebola virus disease, viral hemorrhagic fevers, the role of point-of-care testing in travel medicine, and antibiotic-resistant bacteria in returning travelers and students traveling abroad. - Includes an enhanced drug appendix in the back of the book. |
| artemisinin-based combination therapies: World Malaria Report 2014 World Health Organization, 2015-07-07 The World malaria report 2014 summarizes information received from 97 malaria endemic countries and other sources and updates the analyses presented in 2013. It assesses global and regional malaria trends highlights progress made towards global targets and describes opportunities and challenges in controlling and eliminating the disease. Most of the data presented in this report are for 2013. |
| artemisinin-based combination therapies: Immunity and Inflammation in Health and Disease Shampa Chatterjee, Wolfgang Jungraithmayr, Debasis Bagchi, 2017-08-31 Immunity and Inflammation in Health and Disease: Emerging Roles of Nutraceuticals and Functional Foods in Immune Support provides a comprehensive description of the various pathways by which the vertebrate immune system works, the signals that trigger immune response and how fnew and novel nutraceuticals and functional foods, can be used to contain inflammation and also to boost immunity and immune health. Inflammation is a tool to fight pathogens and the vertebrate immune system has a very complex network of cells to achieve this. However inflammation that goes awry is also the leding cause of several diseases ranging from cardiovascular diseases to diabetes. This book covers the entire gamut from the various cellular players in the inflammation-immune response to its ramifications in terms of protection against pathogens as well as in onset of metabolic, aging and auto-immune related diseases. Finally, the balancing role of dietary nutrients between host defence and immune support is also showcased. The first three scetions explain the various components of the immune system and their modes of activation. The fourth section deals with the ramifications of a robust and execessive inflammatory response. The fifth section is focused on the association between nutrition and immunity and how deficiencies in certain nutrients may affect immunocompetence. The sixth section chapters represent a vision of paradigm shifts within the field and discusses possible future directions. This bool will be a valuable reference for researchers studying immune health either in academia, or in the nutraceutical or functional food industries. Product developers in nutraceutical, supplement, functional food, and health food companies will also appreciate the information presented here. - Conceptualizes the key features in natural products which can boost immune function and immune health - Explains the intricate mechanistic aspects and balance behind immune health - Presents the pathophysiology of several diseases associated with immune system disruption |
| artemisinin-based combination therapies: An Overview of Tropical Diseases Amidou Samie, 2015-12-02 Tropical diseases affect millions of people throughout the world and particularly in the developing countries. The millennium development goals had specifically targeted HIV/AIDS and Malaria for substantial reduction as well as Tuberculosis while many other tropical diseases have been neglected. The new sustainable development goals have not made such distinction and have targeted all diseases for elimination for the improvement of the quality of life of human beings on earth. The present book was developed to provide an update on issues relevant to the treatment of selected tropical diseases such as tuberculosis, malaria, leishmaniasis, schistosomiasis and ectoparasites such as chiggers which are widely distributed throughout the world. The control of these infections has been hampered by the development of drug resistance and the lack of the development of new and more effective drugs. The understanding of the biochemical processes underlying drug activity is therefore essential for the potential elimination of these infections. |
| artemisinin-based combination therapies: SARS , 2004-01-01 SARS is a newly identified human infection caused by a corona virus unlike any other known human or animal virus in its family. The analysis of epidemiological information obtained from the sites of the outbreaks of SARS is still underway but the overall case fatality ratio is known to approach 11% although the rate among the elderly is much higher. Currently the major challenges for the treatment of SARS are: the source of the SARS virus and mode of transmission are still not well understood; there are problems with diagnostic tools; there is no effective treatment; and there is no vaccine for SARS. The above-mentioned difficulties and challenges have motivated national authorities health workers and scientists to explore the potential of complementary treatment. The results of research on integrated treatment with TCM and Western medicine showed that it is safe and that it also has some potential clinical benefits. Therefore the experts suggested that records of such experience could serve as reference material for treatment of SARS in the future. This publication is intended to share experience in the complementary treatment of SARS patients; share the experience of clinical studies in the field of traditional medicine for treatment of SARS between the physicians and researchers; and to further encourage and promote the quality of research in the filed of traditional medicine. |
| artemisinin-based combination therapies: International Travel and Health World Health Organization, 2012 En 4è de couverture : This book explains how travellers can stay healthy and provides WHO guidance on vaccinations, malaria chemoprophylaxis and treatment, personal protection against insects and other disease vectors, and safety in different environmental settings. It covers all the principal risks to travellers' health, both during their journeys and at their destinations. it describes all relevant infectious diseases, including their causative agents, modes of transmission, clinical features and geographical distribution, and provides detials of prophylactic and preventive measures. |
| artemisinin-based combination therapies: World Malaria Report 2016 World Health Organization, 2017-05-09 The World Malaria Report 2016 summarizes information received from malaria-endemic countries and other sources and updates the analyses presented in the 2015 report. The World Malaria Report is WHO's flagship malaria publication released each year in December. It assesses global and regional malaria trends, highlights progress towards global targets, and describes opportunities and challenges in controling and eliminating the disease. Most of the data presented in this report is for 2015. |
Improving malaria case management with artemisinin-based …
May 23, 2023 · 28 through the introduction of highly effective artemisinin-based combination therapies (ACTs) as first-29 line treatment, and the expansion of parasitological diagnosis. …
Triple artemisinin-based combination therapies for malaria: …
combination therapies versus artemisinin-based combination therapies for uncomplicated . Plasmodium falciparum. malaria: a multicentre, open-label, randomised clinical trial. Lancet. …
Artemisinin and artemisinin-based combination therapy …
May 5, 2017 · Artemisinin and artemisinin-based combination therapy resistance Key messages 1. 1Artemisinin resistance is defined as delayed parasite clearance following treatment with an …
Methods for monitoring artemisinin-based combination …
Artemisinin derivatives include dihydroartemisinin, artesunate and artemether. World Health Organization (2015) malaria guideline recommended to treat children and adults with …
Molecular surveillance of Plasmodium falciparum …
strains. We investigated resistance to artemisinin-based combination therapies currently in use in Democratic Republic of Congo by surveying molecular polymorphisms in three genes: pfcrt, …
EFFECTS OF FOUR DIFFERENT CLASSES OF ARTEMISININ
of Artemisinin-Based Combination Therapies o and Lipid Profile of Malaria-Infected Mice. - 163 -INFECTED MICE. AND 1ANWANA, U. I. Uyo. . obongjosekacademical21@gmail.com …
Strategy to Respond to Antimalarial Drug Resistance in Africa
Artemisinin-based combination therapies at the heart of the response •After the spread of chloroquine and SP resistance, artemisinin-based combination therapies (ACTs) became the …
ARTEMISININ BASED COMBINATION THERAPIES AND …
Table 1 Common artemisinin based combination therapies (Modified from Lin et al. [10]) Artemisinin component Elimination half partner drug Partner drug -life of Areas where ACT is …
Q&A on artemisinin resistance - World Health Organization …
Artemisinin-based combination therapies (ACTs) are recommended by WHO as the first-and second-line treatment for uncomplicated P. falciparum malaria as well as for chloroquine …
Editorial Are Artemisinin-Based Combination Therapies For …
artemisinin-based combination therapies (ACTs) to treat malaria. Although ACTs helped to stem the rising tide of malaria mortality in Africa, they faltered in Asia, with delayed clear-ance of …
Assessment of Artemisinin Based Combination Therapy …
Objective: This study was conducted to evaluate the knowledge and utilization of artemisinin based combination therapy (ACT) by PMVs. Methodology: The study was conducted among …
Therapeutic response to four artemisinin-based …
day 3 clearance rates suggest no clinical evidence of artemisinin resistance. This was the fourth of five rounds of TES in Angola showing a corrected AL efficacy <90% in a site. For Zaire, AL …
Malaria morbidity and pyrethroid resistance after the …
funding became available for the use of combination therapies.4,5 During a transitory phase sulfadoxine with pyrimethamine alone or the combination of amodiaquine plus sulfadoxine with …
Review Article: Neuroauditory Toxicity of Artemisinin …
Abstract. Although artemisinin-based combination therapies (ACTs) are widely viewed as safe drugs with a wide therapeutic dose range, concerns about neuroauditory safety of artemisinins …
Artemisinin-based combination with curcumin adds a new …
Artemisinin-based combination with curcumin adds a new dimension to malaria therapy Govindarajan Padmanaban*, V. Arun Nagaraj and Pundi N. Rangarajan ... market has …
Triple Artemisinin-based Combination Therapies (TACTs) …
Triple Artemisinin-based Combination Therapies (TACTs) could reduce the spread or emergence of artemisinin-resistant Plasmodium falciparum malaria DeTACT Project Investigators …
Triple artemisinin-based combination therapies versus …
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised …
Evaluating the Most Commonly Used Artemisinin-Based …
Background: Numerous types of artemisinin-based combination therapies (ACTs) with wide price discrepancies abound in the Nigerian drug market and some of them may be substandard, …
GLOBAL HEALTH IMPACT GROUP Malaria Briefing 2024
(ITNs), indoor residual spraying (IRS), artemisinin-based combination therapies (ACTs), as well as the introduction of new tools and strategies. “Globally, the world has made significant …
Spontaneous Mutations in the Plasmodium falciparum …
Artemisinin-based combination therapies (ACTs) are cur-rently the first-line treatment for uncomplicated falciparum malaria in most areas of endemicity (23, 34). The deployment of …
Availability, market share and price of quality assured …
Nov 17, 2023 · 4 95 private sector co-payment mechanism and integrated into the existing Global Fund grants (12). 96 The AMFm initiative is intended to improve availability, affordability, and …
GUIDELINES - World Health Organization
Artemisinin-based combination therapy (ACT). A combination of an artemisinin derivative with a longer-acting antimalarial that has a different mode of action. Asexual cycle. The life cycle of …
Awareness and Utilisation of Artemisinin-Based …
The recommended treatment for malaria attacks is artemisinin-based combination therapy (ACT) (WHO, 2008). The World Health Assembly resolution in May 2007 urged member states to …
Exploring Barriers and Facilitators of Adherence to …
recommended dosing of two artemisinin-based combination therapies (ACT) to treat uncompli-cated malaria in Freetown, Sierra Leone. This study explored the circumstances and factors that
Tackling antimalarial drug resistance - World Health …
Nov 19, 2020 · Artemisinin-based combination therapies (ACTs) combine an artemisinin derivative (artesunate, artemether or dihydroartemisinin) with a partner drug. The role of the …
Plasmodium falciparum resistance to artemisinin-based …
Table 1. Artemisinin-based combination therapies. Artemether- lumefantrine Coartem® Riamet® (Novartis) Artemether Lumefantrine Hemozoin synthesis Amplification of Pfmdr1 copy number …
Artemisinin and artemisinin-based combination therapy …
Artemisinin and artemisinin-based combination therapy resistance Key messages 1. 1Artemisinin resistance is defined as delayed parasite clearance following treatment with an artesunate …
Methods for monitoring artemisinin-based combination …
Artemisinin derivatives include dihydroartemisinin, artesunate and artemether. World Health Organization (2015) malaria guideline recommended to treat children and adults with …
GLOBAL MALARIA DIAGNOSTIC AND ARTEMISININ …
Global Malaria Diagnostic and Artemisinin Treatment Commodities Demand Forecast Report, May 2018 – Page 6 ABBREVIATIONS ACT(s) artemisinin-based combination …
Updated CDC Recommendations for Using Artemether …
(WHO) has endorsed artemisinin-based combination therapies (ACTs), such as AL, for treatment of uncomplicated malaria during the second and third trimesters of pregnancy and is currently …
Q&A on artemisinin resistance - World Health Organization
Artemisinin-based combination therapies (ACTs) are recommended by WHO as the first-and second-line treatment for uncomplicated P. falciparum malaria as well as for chloroquine …
Availability, market share and price of quality assured …
Nov 17, 2023 · 4 95 private sector co-payment mechanism and integrated into the existing Global Fund grants (12). 96 The AMFm initiative is intended to improve availability, affordability, and …
Policy brief on improving access to artemisinin-based …
Make artemisinin-based combination therapies (ACTs) available at all levels of the health system Involve all healthcare providers in prescribing ACTs and motivating them appropriately …
Pengobatan Malaria Kombinasi Artemisinin (ACT) Di Provinsi …
Pengobatan Malaria Kombinasi Artemisinin (ACT) Di Provinsi Papua Barat Tahun 2013 Artemisinin-based Combination of Antimalaria Therapy (ACT) in West Papua at 2013 Revi …
Chinese plant to a global pharmaceutical - JSTOR
the public sector; leading to a significant shortage of artemisinin-based combination therapies in the private sector (Wolf und Derriennic, 2005:11). There is still limited availability of the drug …
A structural equation modeling of supply chain strategies for ...
Introduction: Malaria is a killer disease in the tropical environment; artemisinin-based combination therapies (ACTs) play a central role in treating malaria. Thus, the supply and presence of ACT ...
Increasing Prevalence of Artemisinin-Resistant HRP2 …
1192 n engl j med 389;13 nejm.org September 28, 2023 The new england journal of medicine A rtemisinin-based combination therapies, which combine fast-acting and potent artemisinin …
Malaria in pregnancy - World Health Organization
artemisinin-based combination therapies (ACTs) in treatment of uncomplicated MiP. A series of prospective cohort studies of pregnant women have been completed to assess pregnancy …
Rationalizing artemisinin-based combination therapies use …
May 7, 2024 · Artemisinin-based combination therapies (ACTs) represent one of the mainstays of malaria control. Despite evidence of the risk of ACTs resistant infections in resource-limited …
Copayment mechanism in selected districts of Uganda: …
Mar 27, 2024 · ity assured artemisinin-based combination therapies (QAACTs) in the private sector [18]. Under the AMFm, public and private importers pay manufacturers a subsidized …
Artemisinin-Based Combination Therapy: Knowledge and
Artemisinin-based Combination Therapies (ACTs). The information generated by this study will help design policy measures to strengthen the training for PMD and treatment component of …
Operational Challenges of Implementing Multiple First-Line …
sulfadoxine–pyrimethamine (SP), should use combination therapies, preferably artemisinin-based combination therapies (ACTs) for the treatment of Plasmodium falciparum malaria. Evidence …
RÉSUMÉ - theses.hal.science
Artemisinin-based Combination Therapies (ACT) are the standard treatments for uncomplicated Plasmodium falciparum malaria. ACTs are composed of two antimalarial molecules: a fast …
combination therapy in Africa - medrxiv.org
May 24, 2023 · 31 artemisinin-based combination therapies (ACTs) is unknown. This study aims to estimate this 32 proportion and the excess number of treatment failures (recrudescences) …
Résistance de l’agent du paludisme, Plasmodium falciparum …
Plasmodium falciparum resistance to artemisinin-based combination therapies (ACTs): Fears of widespread drug resistance Key-words: Malaria. artemisinin. Drug Resistance. Parasite. …
Evolution of Partial Resistance to Artemisinins in Malaria …
Aug 24, 2023 · misinin-based combination therapies, the most important malaria drugs, emerged ... decreased efficacies of artemisinin-based combi - nation therapies in Southeast Asia. 9,10 …
Discrete Survival Model Analysis of Plasmodium falciparum …
Abstract: The need to monitor changes in parasite clearance following treatment with artemisinin-based combination therapies (ACTs) is important in the containment of drug resistance. This …
International Journal of Drug Development & Research
Comparative assessment of two Artemisinin based combination Therapies in the treatment of Uncomplicated Malaria among University students in Nigeria Okonta Matthew J. 1, Nduka …
Pregnancy outcomes after first-trimester treatment with …
Artemisinin-based combination therapies (ACTs) are a highly effective, first-line treatment for uncomplicated . Plasmodium falciparum . malaria, except in the first trimester of pregnancy, …
William C. Campbell and Satoshi Ōmura - NobelPrize.org
combination therapy, it is estimated to reduce mortality from Malaria by more than 20% overall and by more than 30% in children. For Africa alone, this means that more than 100 000 lives …
